Histogen jumps on getting patent for inflammatory disease drug

Histogen

17/03/2023 11:15

** Shares of Drug developer Histogen Inc  HSTO.O  rise 34.5%
to $1.16; amongst biggest pct gainers across U.S. stock
exchanges premarket
    ** Co says it has been granted patent for its experimental
drug, CTS-2090, to treat certain inflammatory diseases
 urn:newsml:reuters.com:*:nGNX3BVq3l
    ** Patent is expected to provide protection to drug till
2040 - HSTO
    ** HSTO is currently developing the drug to protect against
inflammation driven damage to the lining of gastrointestinal
tract and also weight loss in patients with ulcerative colitis
    ** HSTO was down ~88% last year

 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))